CL2016001192A1 - Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. - Google Patents
Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.Info
- Publication number
- CL2016001192A1 CL2016001192A1 CL2016001192A CL2016001192A CL2016001192A1 CL 2016001192 A1 CL2016001192 A1 CL 2016001192A1 CL 2016001192 A CL2016001192 A CL 2016001192A CL 2016001192 A CL2016001192 A CL 2016001192A CL 2016001192 A1 CL2016001192 A1 CL 2016001192A1
- Authority
- CL
- Chile
- Prior art keywords
- dhodh
- inhibitor
- neurodegenerative diseases
- treat neurodegenerative
- dihydroorate dehydrogenase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
METODO PARA EL TRATAMIENTO DE ELA QUE COMPRENDDE UN COMPUESTO INHIBIDOR DE DIHIDROORATO DESHIDROGENASA (DHODH); COMPOSICION FARMACEUTICA; UN KIT
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908019P | 2013-11-22 | 2013-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001192A1 true CL2016001192A1 (es) | 2017-01-13 |
Family
ID=52146688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001192A CL2016001192A1 (es) | 2013-11-22 | 2016-05-18 | Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160287549A1 (es) |
EP (1) | EP3071199A2 (es) |
JP (1) | JP2016537360A (es) |
KR (1) | KR20160079123A (es) |
CN (1) | CN105916522A (es) |
AU (1) | AU2014352920A1 (es) |
CA (1) | CA2930429A1 (es) |
CL (1) | CL2016001192A1 (es) |
EA (1) | EA201691057A1 (es) |
IL (1) | IL245541A0 (es) |
MX (1) | MX2016006678A (es) |
PH (1) | PH12016500903A1 (es) |
TN (1) | TN2016000197A1 (es) |
WO (1) | WO2015077535A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017056104A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Limited | Stable pharmaceutical compositions of teriflunomide |
CN107382902B (zh) * | 2016-05-17 | 2022-08-12 | 华东理工大学 | 噻唑类衍生物及其应用 |
JP7231628B2 (ja) * | 2017-11-23 | 2023-03-01 | イミュニック アクチェンゲゼルシャフト | 慢性炎症性疾患および/または自己免疫疾患の予防または治療における使用のためのビドフルジムス(Vidofludimus)の投与レジメン |
EP3813822A4 (en) * | 2018-06-27 | 2022-03-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | SOLID PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING TERIFLUNOMIDE |
US11877994B2 (en) | 2021-08-02 | 2024-01-23 | Immunic Ag | Treatment of multiple sclerosis comprising DHODH inhibitors |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL186239B (nl) | 1975-06-05 | Hoechst Ag | Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze. | |
US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US5032597A (en) | 1983-07-22 | 1991-07-16 | Du Pont Merck Pharmaceutical | Method of using phenylquinolinecarboxylic acids and derivatives for lymthoid leukemia treatment in a mammal |
US4680299A (en) | 1984-04-30 | 1987-07-14 | E.I. Du Pont De Nemours And Company | 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof |
AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
US4639454A (en) | 1985-01-17 | 1987-01-27 | E. I. Du Pont De Nemours And Company | Phenylquinazolinecarboxylic acids and derivatives as cancer chemotherapeutic agents |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
GB8619433D0 (en) | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
GB8619432D0 (en) | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
US4847381A (en) | 1987-08-31 | 1989-07-11 | American Cyanamid Company | 2-Phenyl-4-quinoline carboxylic acids |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
US4861783A (en) | 1988-04-26 | 1989-08-29 | E. I. Du Pont De Nemours And Company | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases |
US4968701A (en) | 1988-04-26 | 1990-11-06 | E. I. Du Pont De Nemours And Company | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents |
US4968702A (en) | 1989-01-17 | 1990-11-06 | American Cyanamid Company | Substituted quinolinecarboxylic acids |
US4918077A (en) | 1989-01-25 | 1990-04-17 | E. I. Du Pont De Nemours & Co., Inc. | 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
US5135934A (en) | 1990-07-06 | 1992-08-04 | Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents |
US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
IL99811A (en) | 1990-10-30 | 1996-03-31 | Roussel Uclaf | 3-Cycloalkyl-propanamides, tautomeric forms of these, their salts, method of preparation, use as drugs and preparations containing them |
IL102790A (en) | 1991-09-17 | 1996-01-31 | Roussel Uclaf | History of 3-cycloalkyl-prop-2-anamide |
EP0538783B1 (de) | 1991-10-23 | 1995-09-27 | Hoechst Aktiengesellschaft | N-phenyl-2-cyano-3-hydroxycrotonsäureamidderivate und deren Verwendung als Arzneimittel mit immunmodulatorischer Eigenschaft |
GB9200275D0 (en) | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
DK0601191T3 (da) | 1992-04-24 | 1999-04-26 | Kyowa Hakko Kogyo Kk | Hidtil ukendt tetracyklisk forbindelse |
GB9209330D0 (en) | 1992-04-30 | 1992-06-17 | Roussel Lab Ltd | Chemical compounds |
GB9300083D0 (en) | 1993-01-05 | 1993-03-03 | Roussel Lab Ltd | Chemical compounds |
WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
JP3272808B2 (ja) | 1993-04-28 | 2002-04-08 | 協和醗酵工業株式会社 | 新規四環系化合物 |
US5393891A (en) | 1993-06-08 | 1995-02-28 | The Du Pont Merck Pharmaceutical Company | Immunoassay reagents and methods for detecting brequinar and analogs |
GB9313365D0 (en) | 1993-06-29 | 1993-08-11 | Roussel Lab Ltd | Chemical compounds |
US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
WO1995009153A1 (fr) | 1993-09-28 | 1995-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau compose tetracyclique |
GB9320299D0 (en) | 1993-10-01 | 1993-11-17 | Roussel Lab Ltd | Isoxazole derivatives |
GB9322781D0 (en) | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5523408A (en) | 1994-03-25 | 1996-06-04 | The Dupont Merck Pharmaceutical Company | 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents |
JPH083163A (ja) | 1994-06-22 | 1996-01-09 | Kyowa Hakko Kogyo Co Ltd | 縮合ピリジン誘導体 |
GB9520092D0 (en) | 1995-10-02 | 1995-12-06 | Hoechst Roussel Ltd | Chemical compounds |
AU2896097A (en) | 1996-05-10 | 1997-12-05 | Novartis Ag | Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation |
DE19636974A1 (de) | 1996-09-12 | 1998-03-19 | Hoechst Ag | 2-Cyano-3,5-dihydroxy-hex-2-en- carbonsäureamidderivate |
JPH10231289A (ja) | 1996-12-06 | 1998-09-02 | Kyowa Hakko Kogyo Co Ltd | 四環系キノリン誘導体 |
US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
US20040265375A1 (en) * | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
US20110009460A1 (en) * | 2009-06-19 | 2011-01-13 | Valentin Gribkoff | Compositions and methods for treating amyotrophic lateral sclerosis |
MX336663B (es) * | 2009-09-18 | 2016-01-27 | Sanofi Sa | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada. |
UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат |
-
2014
- 2014-11-21 AU AU2014352920A patent/AU2014352920A1/en not_active Abandoned
- 2014-11-21 JP JP2016530840A patent/JP2016537360A/ja active Pending
- 2014-11-21 WO PCT/US2014/066766 patent/WO2015077535A2/en active Application Filing
- 2014-11-21 US US15/038,185 patent/US20160287549A1/en not_active Abandoned
- 2014-11-21 EP EP14819148.9A patent/EP3071199A2/en not_active Withdrawn
- 2014-11-21 KR KR1020167016071A patent/KR20160079123A/ko not_active Application Discontinuation
- 2014-11-21 CA CA2930429A patent/CA2930429A1/en not_active Abandoned
- 2014-11-21 TN TN2016000197A patent/TN2016000197A1/en unknown
- 2014-11-21 EA EA201691057A patent/EA201691057A1/ru unknown
- 2014-11-21 CN CN201480073657.9A patent/CN105916522A/zh active Pending
- 2014-11-21 MX MX2016006678A patent/MX2016006678A/es unknown
-
2016
- 2016-05-08 IL IL245541A patent/IL245541A0/en unknown
- 2016-05-16 PH PH12016500903A patent/PH12016500903A1/en unknown
- 2016-05-18 CL CL2016001192A patent/CL2016001192A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160079123A (ko) | 2016-07-05 |
TN2016000197A1 (en) | 2017-10-06 |
AU2014352920A1 (en) | 2016-06-23 |
WO2015077535A3 (en) | 2015-08-20 |
CA2930429A1 (en) | 2015-05-28 |
EP3071199A2 (en) | 2016-09-28 |
US20160287549A1 (en) | 2016-10-06 |
MX2016006678A (es) | 2016-09-13 |
JP2016537360A (ja) | 2016-12-01 |
CN105916522A (zh) | 2016-08-31 |
PH12016500903A1 (en) | 2016-06-20 |
WO2015077535A2 (en) | 2015-05-28 |
EA201691057A1 (ru) | 2016-10-31 |
IL245541A0 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
BR112019003914A2 (pt) | inibidores de processos metabólicos celulares | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
CL2016001636A1 (es) | Mezclas fungicidas sinérgicas para el control fúngico en cereales | |
CL2015002164A1 (es) | Formulación combinada de dos compuesos antivirales. | |
UY35787A (es) | Composiciones útiles para tratar trastornos relacionados con kit | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
EA201690753A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
EA201890239A3 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
EA201691421A1 (ru) | Гетероарилы и их применение | |
CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
CL2016001192A1 (es) | Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas. | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
BR112015029462A2 (pt) | Inibidores de quinase | |
CL2016001362A1 (es) | Composiciones y métodos para reducir eventos adversos cardiovasculares graves | |
CL2014002978A1 (es) | Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos | |
ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
MX2015010077A (es) | Terapia de combinacion para el tratamiento de neumonia nosocomial. | |
BR112017008481A2 (pt) | composto antimicótico | |
BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2019003069A (es) | Uso de pridopidina para tratar el sindrome de rett. |